Neurocrine Biosciences Announces Publication in Orphanet Journal of Rare Diseases Advancing Understanding of Hyperphagia in Prader-Willi Syndrome
Key Highlights
- ➤VYKAT XR is FDA-approved and commercially available for PWS hyperphagia
- ➤VYKAT XR treats adults and children aged 4 and older with PWS
- ➤Publication emphasizes multidimensional assessment and integrated lifelong care
- ➤Hyperphagia reflects hypothalamic, behavioral, and environmental factors beyond obesity
- ➤Transition periods may worsen symptoms and increase health risks
Expert Statements
Eiry W. Roberts, M.D., Chief Medical Officer of Neurocrine Biosciences
“Neurocrine is committed to advancing understanding of Prader-Willi syndrome and addressing the needs of individuals and families affected by this complex disorder. Recognizing hyperphagia as a multifaceted, neurobehavioral condition is essential to understanding its real-world impact on people with PWS and their families. By connecting the underlying disease biology with the daily experience of hyperphagia, these expert perspectives can help inform how best to assess and manage the symptoms and thus support continued progress in care for the PWS community.”
Maithé Tauber, M.D., Professor Emeritus of Pediatrics at Université Toulouse III and lead author of the publication
“Hyperphagia in Prader-Willi syndrome extends far beyond hunger or food intake. It affects behavior, autonomy, and daily life for individuals living with PWS and their families. Improving care will rely on a truly integrated approach, one that deepens our understanding of the underlying biology, reflects the experience of individuals and their families, and actively engages healthcare teams within well-coordinated systems of care that support patients from birth throughout their lives.”
Neurocrine Biosciences Announces Publication in Orphanet Journal of Rare Diseases Advancing Understanding of Hyperphagia in Prader-Willi Syndrome PR Newswire
* Expert perspectives highlight the interaction of hypothalamic dysfunction, biological, behavioral, and environmental factors in shaping the challenges of hyperphagia in Prader-Willi syndrome for patients and families beyond obesity-related complications * The manuscript underscores the importance of multidimensional assessment and integrated care management across the patient lifespan * Experts conclude VYKAT(®) XR (diazoxide choline) extended-release tablets represent a significant advancement in the treatment of hyperphagia, potentially complementing behavioral and environmental approaches SAN DIEGO, Oct. 22, 2026 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced a publication of expert perspectives highlighting hyperphagia in Prader-Willi syndrome (PWS) as a complex, neurobiologically driven condition that extends beyond excessive hunger and requires comprehensive assessment and management across the patient lifespan. The publication provides insights from an international group of clinical and scientific experts on the evolving understanding of hyperphagia and its implications for the care of people with PWS. The manuscript appears in Orphanet Journal of Rare Diseases .
Get started
Create a free account to read the full story.